JP2006503913A - 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 - Google Patents
高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 Download PDFInfo
- Publication number
- JP2006503913A JP2006503913A JP2005501572A JP2005501572A JP2006503913A JP 2006503913 A JP2006503913 A JP 2006503913A JP 2005501572 A JP2005501572 A JP 2005501572A JP 2005501572 A JP2005501572 A JP 2005501572A JP 2006503913 A JP2006503913 A JP 2006503913A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- benzalkonium chloride
- eye drop
- ophthalmic
- solubilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 title claims abstract description 38
- 229960001160 latanoprost Drugs 0.000 title claims abstract description 34
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 19
- 206010030043 Ocular hypertension Diseases 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 23
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 36
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 208000035475 disorder Diseases 0.000 claims abstract description 11
- 208000001344 Macular Edema Diseases 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 206010025415 Macular oedema Diseases 0.000 claims abstract description 9
- 201000010230 macular retinal edema Diseases 0.000 claims abstract description 9
- 239000003889 eye drop Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 21
- 239000002997 ophthalmic solution Substances 0.000 claims description 19
- 229940054534 ophthalmic solution Drugs 0.000 claims description 17
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229940068968 polysorbate 80 Drugs 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 8
- 229960004605 timolol Drugs 0.000 claims description 8
- 229940012356 eye drops Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 5
- -1 polyoxyethylene Polymers 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000003885 eye ointment Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 229940002639 xalatan Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940110775 latanoprost ophthalmic solution Drugs 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229960001446 distigmine Drugs 0.000 description 1
- GJHSNEVFXQVOHR-UHFFFAOYSA-L distigmine bromide Chemical compound [Br-].[Br-].C=1C=C[N+](C)=CC=1OC(=O)N(C)CCCCCCN(C)C(=O)OC1=CC=C[N+](C)=C1 GJHSNEVFXQVOHR-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- RJTZUHVCZIGJMB-UHFFFAOYSA-N hydron;1h-indole;chloride Chemical compound Cl.C1=CC=C2NC=CC2=C1 RJTZUHVCZIGJMB-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 229940127242 parasympathomimetic drug Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960002516 physostigmine salicylate Drugs 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Solid Thermionic Cathode (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42077602P | 2002-10-24 | 2002-10-24 | |
| US42104402P | 2002-10-25 | 2002-10-25 | |
| US10/429,677 US7074827B2 (en) | 2002-10-24 | 2003-05-06 | Method for treating ocular hypertension and glaucoma |
| PCT/JP2003/013452 WO2004037267A1 (en) | 2002-10-24 | 2003-10-22 | Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012125019A Division JP2012162570A (ja) | 2002-10-24 | 2012-05-31 | 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006503913A true JP2006503913A (ja) | 2006-02-02 |
| JP2006503913A5 JP2006503913A5 (enExample) | 2006-12-07 |
Family
ID=32110845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501572A Pending JP2006503913A (ja) | 2002-10-24 | 2003-10-22 | 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 |
| JP2012125019A Pending JP2012162570A (ja) | 2002-10-24 | 2012-05-31 | 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012125019A Pending JP2012162570A (ja) | 2002-10-24 | 2012-05-31 | 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7074827B2 (enExample) |
| EP (2) | EP1553953B1 (enExample) |
| JP (2) | JP2006503913A (enExample) |
| AT (1) | ATE480240T1 (enExample) |
| AU (1) | AU2003274734A1 (enExample) |
| CA (1) | CA2502437C (enExample) |
| DE (1) | DE60334134D1 (enExample) |
| DK (1) | DK1553953T3 (enExample) |
| WO (1) | WO2004037267A1 (enExample) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008096804A1 (ja) * | 2007-02-07 | 2008-08-14 | Teika Pharmaceutical Co., Ltd. | ラタノプロスト含有点眼剤 |
| JP2008247828A (ja) * | 2007-03-30 | 2008-10-16 | Wakamoto Pharmaceut Co Ltd | ラタノプロストを含有する水性医薬組成物。 |
| JP2009040727A (ja) * | 2007-08-09 | 2009-02-26 | Towa Yakuhin Kk | ラタノプロストを有効成分とする安定な点眼液剤 |
| WO2009028674A1 (ja) * | 2007-08-29 | 2009-03-05 | Wakamoto Pharmaceutical Co., Ltd. | ラタノプロスト含有水性医薬組成物 |
| JP2010275259A (ja) * | 2009-05-29 | 2010-12-09 | Toa Yakuhin Kk | 均一、かつ安定なラタノプロスト点眼液剤組成物 |
| JP2013511494A (ja) * | 2009-11-19 | 2013-04-04 | ノバガリ ファーマ エスエー | 角膜および結膜病変を治癒させるためのプロスタグランジンＦ２αおよび類似体の使用 |
| JP2013522272A (ja) * | 2010-03-17 | 2013-06-13 | ノバリック ゲーエムベーハー | 眼圧上昇の治療のための医薬組成物 |
| JP2013532159A (ja) * | 2010-06-29 | 2013-08-15 | ラボラトワール テア | 防腐剤を含まない非粘性プロスタグランジン系点眼液用のポリマー送達システム |
| WO2015029923A1 (ja) * | 2013-08-26 | 2015-03-05 | ロート製薬株式会社 | 眼科用製剤 |
| US9999593B2 (en) | 2008-05-30 | 2018-06-19 | Santen Pharmaceutical Co., Ltd. | Method and composition for treating ocular hypertension and glaucoma |
| JP2022120120A (ja) * | 2022-06-13 | 2022-08-17 | 東亜薬品株式会社 | 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法 |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244768B2 (en) * | 2003-10-03 | 2007-07-17 | Allergan, Inc. | Compositions and methods comprising prostaglandin related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia |
| EP1655021B1 (en) * | 2004-11-09 | 2008-10-29 | Novagali Pharma SA | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
| GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
| DE102005035986B4 (de) * | 2005-07-28 | 2009-10-15 | Bausch & Lomb Incorporated | Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat |
| JP5247453B2 (ja) * | 2005-10-10 | 2013-07-24 | ノバガリ ファルマ エスア | プロスタグランジン含有眼科用カチオン性水中油型エマルジョン |
| US7666912B2 (en) * | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
| TWI394564B (zh) * | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
| KR101421519B1 (ko) * | 2006-09-28 | 2014-07-30 | 알콘 리서치, 리미티드 | 자기 보존 수성 약제학적 조성물 |
| FR2912207B1 (fr) * | 2007-02-01 | 2012-10-26 | Air Liquide | Procede et appareil de production de monoxyde de carbone par distillation cryogenique |
| FR2918891B1 (fr) * | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| MX2007011165A (es) * | 2007-09-12 | 2009-03-11 | Arturo Jimenez Bayardo | Composición farmacéutica estable de timolol, dorzolamida y brimonidina. |
| TWI544927B (zh) | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物 |
| CN101959500A (zh) * | 2008-03-17 | 2011-01-26 | 爱尔康研究有限公司 | 包含硼酸类化合物-多元醇络合物的水性药物组合物 |
| EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| TWI489997B (zh) | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸－多元醇錯合物之水性藥學組成物 |
| EP2269575A1 (en) | 2009-06-30 | 2011-01-05 | Santen Pharmaceutical Co., Ltd | Method for improving bioavailability of latanoprost |
| US20130245124A1 (en) * | 2010-07-29 | 2013-09-19 | Allergan, Inc. | Preservative free bimatoprost solutions |
| DK2598118T3 (en) | 2010-07-29 | 2018-12-10 | Allergan Inc | CONSERVATIVE-FREE BIMATOPROST AND TIMOLOL SOLUTIONS |
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| EP2452669A1 (en) | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Ophthalmic composition |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| CA2866067C (en) | 2011-01-19 | 2015-04-21 | Topokine Therapeutics, Inc. | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| CN104640638B (zh) * | 2012-04-10 | 2018-01-05 | 艾诺维亚股份有限公司 | 提供电荷分离和可控制的微滴电荷，和低剂量体积眼的施用的喷雾喷射器机械装置和设备 |
| ES2663879T3 (es) | 2012-04-20 | 2018-04-17 | Eyenovia, Inc. | Dispositivo eyector de pulverización y métodos de uso |
| CA2873276A1 (en) | 2012-05-14 | 2013-11-21 | Eyenovia, Inc. | Laminar flow droplet generator device and methods of use |
| SG11201407431RA (en) | 2012-05-15 | 2014-12-30 | Eyenovia Inc | Ejector devices, methods, drivers, and circuits therefor |
| CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| CA2883003C (en) | 2012-09-12 | 2021-11-16 | Novaliq Gmbh | Semifluorinated alkane compositions |
| WO2014081941A1 (en) | 2012-11-21 | 2014-05-30 | Topokine Therapeutics, Inc. | Methods and compositions for locally increasing body fat |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| NO2753788T3 (enExample) | 2013-05-10 | 2018-06-16 | ||
| US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
| GR1008483B (el) * | 2013-12-23 | 2015-05-12 | Rafarm Α.Ε.Β.Ε., | Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης |
| US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| JP6604328B2 (ja) | 2014-08-05 | 2019-11-13 | ソニー株式会社 | 直流電力送電装置、直流電力受電装置及び直流電力送電システム |
| DK3722274T3 (da) | 2015-09-30 | 2023-09-11 | Novaliq Gmbh | 2-perfluorbutylpentan til oftalmisk indgivelse |
| DE202016008738U1 (de) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorierte Verbindungen und ihre Zusammensetzungen |
| GR1009040B (el) * | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου |
| ES2763121T3 (es) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Método de administración tópica |
| CA3036297C (en) | 2016-09-22 | 2023-09-05 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| ES2965883T3 (es) | 2016-12-23 | 2024-04-17 | Novaliq Gmbh | Composición oftálmica para el tratamiento de la enfermedad del ojo seco |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| CA3076776A1 (en) | 2017-09-27 | 2019-04-04 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| CN120022260A (zh) | 2017-10-04 | 2025-05-23 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| WO2019166631A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| EP3784246A1 (en) | 2018-04-27 | 2021-03-03 | Novaliq GmbH | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| AU2019358249B2 (en) | 2018-10-12 | 2024-02-22 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| HUE064366T2 (hu) | 2019-08-07 | 2024-03-28 | Aneira Pharma Inc | Készítmények hajhullás kezelésére |
| KR20220058577A (ko) | 2019-09-06 | 2022-05-09 | 노바리크 게엠베하 | 포도막염 치료를 위한 안과용 조성물 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5578618A (en) * | 1988-09-06 | 1996-11-26 | Pharmacia Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| JPH10259179A (ja) * | 1996-09-19 | 1998-09-29 | Santen Pharmaceut Co Ltd | 多置換アリールオキシ基を有するプロスタグランジン類およびその用途 |
| JP2001335511A (ja) * | 1999-12-01 | 2001-12-04 | Sankyo Co Ltd | 緑内障を治療するための併用剤 |
| WO2002038158A1 (en) * | 2000-11-13 | 2002-05-16 | Pharmacia Ab | Improved treatment |
| JP2002161037A (ja) * | 2000-09-13 | 2002-06-04 | Santen Pharmaceut Co Ltd | 点眼液 |
| US20020103255A1 (en) * | 1997-12-19 | 2002-08-01 | Hellberg Mark R. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| AU7680096A (en) | 1995-12-22 | 1997-07-17 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| AR002194A1 (es) * | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| SE0002211D0 (sv) | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| US20020035148A1 (en) * | 2000-07-20 | 2002-03-21 | Ryuji Ueno | Treatment of ocular hypertension |
| CA2422031C (en) | 2000-09-13 | 2011-11-15 | Santen Pharmaceutical Co., Ltd. | Ophthalmic solutions comprising difluoroprostaglandin f2 alpha |
| US7249174B2 (en) * | 2002-06-12 | 2007-07-24 | Bladelogic, Inc. | Method and system for executing and undoing distributed server change operations |
| AU2003262268A1 (en) * | 2002-08-23 | 2004-04-30 | Santen Pharmaceutical Co., Ltd. | Stable eye drops containing latanoprost as the active ingredient |
| EP1547599B1 (en) | 2002-09-09 | 2017-11-01 | Santen Pharmaceutical Co., Ltd. | Transparent eye drops containing latanoprost |
-
2003
- 2003-05-06 US US10/429,677 patent/US7074827B2/en not_active Expired - Fee Related
- 2003-10-22 CA CA2502437A patent/CA2502437C/en not_active Expired - Fee Related
- 2003-10-22 WO PCT/JP2003/013452 patent/WO2004037267A1/en not_active Ceased
- 2003-10-22 DK DK03758746.6T patent/DK1553953T3/da active
- 2003-10-22 EP EP03758746A patent/EP1553953B1/en not_active Expired - Lifetime
- 2003-10-22 JP JP2005501572A patent/JP2006503913A/ja active Pending
- 2003-10-22 EP EP10171708A patent/EP2253322A1/en not_active Withdrawn
- 2003-10-22 AU AU2003274734A patent/AU2003274734A1/en not_active Abandoned
- 2003-10-22 DE DE60334134T patent/DE60334134D1/de not_active Expired - Lifetime
- 2003-10-22 AT AT03758746T patent/ATE480240T1/de active
-
2006
- 2006-05-23 US US11/438,290 patent/US8673973B2/en not_active Expired - Fee Related
-
2012
- 2012-05-31 JP JP2012125019A patent/JP2012162570A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5578618A (en) * | 1988-09-06 | 1996-11-26 | Pharmacia Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| JPH10259179A (ja) * | 1996-09-19 | 1998-09-29 | Santen Pharmaceut Co Ltd | 多置換アリールオキシ基を有するプロスタグランジン類およびその用途 |
| US20020103255A1 (en) * | 1997-12-19 | 2002-08-01 | Hellberg Mark R. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| JP2001335511A (ja) * | 1999-12-01 | 2001-12-04 | Sankyo Co Ltd | 緑内障を治療するための併用剤 |
| JP2002161037A (ja) * | 2000-09-13 | 2002-06-04 | Santen Pharmaceut Co Ltd | 点眼液 |
| WO2002038158A1 (en) * | 2000-11-13 | 2002-05-16 | Pharmacia Ab | Improved treatment |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013189450A (ja) * | 2007-02-07 | 2013-09-26 | Teika Seiyaku Kk | ラタノプロスト含有点眼液組成物 |
| WO2008096804A1 (ja) * | 2007-02-07 | 2008-08-14 | Teika Pharmaceutical Co., Ltd. | ラタノプロスト含有点眼剤 |
| JPWO2008096804A1 (ja) * | 2007-02-07 | 2010-05-27 | テイカ製薬株式会社 | ラタノプロスト含有点眼剤 |
| JP2008247828A (ja) * | 2007-03-30 | 2008-10-16 | Wakamoto Pharmaceut Co Ltd | ラタノプロストを含有する水性医薬組成物。 |
| JP2009040727A (ja) * | 2007-08-09 | 2009-02-26 | Towa Yakuhin Kk | ラタノプロストを有効成分とする安定な点眼液剤 |
| US9456980B2 (en) | 2007-08-29 | 2016-10-04 | Wakamoto Pharmaceutical Co., Ltd. | Latanoprost-containing aqueous pharmaceutical composition |
| WO2009028674A1 (ja) * | 2007-08-29 | 2009-03-05 | Wakamoto Pharmaceutical Co., Ltd. | ラタノプロスト含有水性医薬組成物 |
| US9999593B2 (en) | 2008-05-30 | 2018-06-19 | Santen Pharmaceutical Co., Ltd. | Method and composition for treating ocular hypertension and glaucoma |
| US10864159B2 (en) | 2008-05-30 | 2020-12-15 | Santen Pharmaceutical Co., Ltd. | Method and composition for treating ocular hypertension and glaucoma |
| JP2010275259A (ja) * | 2009-05-29 | 2010-12-09 | Toa Yakuhin Kk | 均一、かつ安定なラタノプロスト点眼液剤組成物 |
| JP2013511494A (ja) * | 2009-11-19 | 2013-04-04 | ノバガリ ファーマ エスエー | 角膜および結膜病変を治癒させるためのプロスタグランジンＦ２αおよび類似体の使用 |
| JP2013522272A (ja) * | 2010-03-17 | 2013-06-13 | ノバリック ゲーエムベーハー | 眼圧上昇の治療のための医薬組成物 |
| JP2013532159A (ja) * | 2010-06-29 | 2013-08-15 | ラボラトワール テア | 防腐剤を含まない非粘性プロスタグランジン系点眼液用のポリマー送達システム |
| JP2015038099A (ja) * | 2010-06-29 | 2015-02-26 | ラボラトワール テアＬａｂｏｒａｔｏｉｒｅｓ Ｔｈｅａ | 防腐剤を含まない非粘性プロスタグランジン系点眼液用のポリマー送達システム |
| KR101809713B1 (ko) * | 2010-06-29 | 2017-12-15 | 라보라토이레스 테아 | 방부제 없는 프로스타글란딘계 비점성 용액의 고분자 전달 시스템 |
| WO2015029923A1 (ja) * | 2013-08-26 | 2015-03-05 | ロート製薬株式会社 | 眼科用製剤 |
| JP2022120120A (ja) * | 2022-06-13 | 2022-08-17 | 東亜薬品株式会社 | 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20040082660A1 (en) | 2004-04-29 |
| CA2502437C (en) | 2012-07-17 |
| ATE480240T1 (de) | 2010-09-15 |
| AU2003274734A1 (en) | 2004-05-13 |
| EP2253322A1 (en) | 2010-11-24 |
| DE60334134D1 (de) | 2010-10-21 |
| CA2502437A1 (en) | 2004-05-06 |
| EP1553953A1 (en) | 2005-07-20 |
| US8673973B2 (en) | 2014-03-18 |
| DK1553953T3 (da) | 2010-10-25 |
| WO2004037267A1 (en) | 2004-05-06 |
| US20060205725A1 (en) | 2006-09-14 |
| US7074827B2 (en) | 2006-07-11 |
| JP2012162570A (ja) | 2012-08-30 |
| EP1553953B1 (en) | 2010-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006503913A (ja) | 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物 | |
| JP7726542B2 (ja) | ピリジルアミノ酢酸化合物を含む医薬製剤 | |
| US8637054B2 (en) | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives | |
| CN100391461C (zh) | 降血压性脂质和噻吗洛尔组合物及其使用的方法 | |
| US10792288B2 (en) | Preservative free brimonidine and timolol solutions | |
| EP2316420B1 (en) | Topical ophthalmic composition to reduce pain | |
| KR20140056280A (ko) | 비마토프로스트 및 브리모니딘의 고정된 용량 조합 | |
| JP2022508715A (ja) | 緑内障および関連状態の処置のための方法および組成物 | |
| JP2021095406A (ja) | ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤 | |
| US20240216334A1 (en) | Methods and compositions for treating mydriasis, glaucoma, and other ocularconditions | |
| JPH078788B2 (ja) | 散瞳作用を有する眼科用医薬組成物 | |
| WO2011027778A1 (ja) | 高眼圧症および緑内障処置のための眼局所投与用組成物 | |
| US20020077358A1 (en) | Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgery | |
| JPWO2000038689A1 (ja) | 高眼圧症あるいは緑内障の処置用医薬組成物 | |
| WO2025159135A1 (ja) | 緑内障または高眼圧症に罹患している患者における夜間睡眠時の眼圧を下降させるためのセペタプロストを含有する点眼液 | |
| ES2349699T3 (es) | Método y composición que contiene latanoprost para tratar la hipertensión ocular y el glaucoma. | |
| WO2000043015A1 (fr) | Gouttes ophtalmologiques | |
| WO2019123266A1 (en) | Ophthalmic composition having a prostaglandin and a beta-blocker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061017 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100518 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100810 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100817 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110315 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110602 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110609 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110913 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120131 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120531 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120730 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120810 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131129 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131204 |